{"id":"ixchiq","rwe":[{"pmid":"41864594","year":"2026","title":"Towards national guidance on dengue and chikungunya vaccination in travellers: Lessons from global recommendations.","finding":"","journal":"Travel medicine and infectious disease","studyType":"Clinical Study"},{"pmid":"41863914","year":"2026","title":"Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ).","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"41859051","year":"2026","title":"Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review.","finding":"","journal":"Infection and drug resistance","studyType":"Clinical Study"},{"pmid":"41733825","year":"2026","title":"Travel-Related Challenges of Chikungunya Virus and Vaccination Options.","finding":"","journal":"Journal of epidemiology and global health","studyType":"Clinical Study"},{"pmid":"41679405","year":"2026","title":"New progress in the global expansion and prevention of chikungunya fever.","finding":"","journal":"Acta tropica","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Centre Hospitalier Universitaire de la Réunion","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Headache","drugRate":"31.6%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"28.5%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"23.9%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"17.2%","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"13.5%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"11.2%","severity":"common","organSystem":""},{"effect":"Tenderness (injection site)","drugRate":"10.6%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Centre Hospitalier Universitaire de la Réunion","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IXCHIQ","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:45:59.616465+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ixchiq","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:46:09.152146+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:46:07.572235+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IXCHIQ","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:46:08.507810+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068495/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:46:08.978616+00:00"}},"allNames":["ixchiq"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Ixchiq is a small molecule that likely works through a specific binding interaction with its target, potentially altering its activity or expression to produce a therapeutic effect."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Chikungunya_vaccine","title":"Chikungunya vaccine","extract":"Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus. As of 2025, two vaccines have been licensed in some countries. These are Ixchiq, a live attenuated vaccine from Valneva, and Vimkunya manufactured by Bavarian Nordic which utilises virus-like particle technology.","wiki_history":"== History ==\nIn November 2023, the US Food and Drug Administration (FDA) granted the application for the chikungunya vaccine with fast track, breakthrough therapy, and priority review designations. It contains the live attenuated chikungunya virus (CHIKV) Δ5nsP3 strain of the ECSA/IOL genotype. A second vaccine,  Vimkunya, manufactured by Bavarian Nordic, was authorized for medical use in the European Union in February 2025."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=ixchiq","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ixchiq","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Chikungunya_vaccine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:22:15.559527","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:46:10.916663+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"ixchiq","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06928753","phase":"PHASE4","title":"Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2025-04-18","conditions":["Chikungunya Virus Infection"],"enrollment":1800,"completionDate":"2026-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL6068495"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Centre Hospitalier Universitaire de la Réunion","relationship":"Original Developer"}],"publicationCount":39,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Centre Hospitalier Universitaire de la Réunion","recentPublications":[{"date":"2026 Mar 20","pmid":"41864594","title":"Towards national guidance on dengue and chikungunya vaccination in travellers: Lessons from global recommendations.","journal":"Travel medicine and infectious disease"},{"date":"2026 Mar 20","pmid":"41863914","title":"Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ).","journal":"Vaccine"},{"date":"2026","pmid":"41859051","title":"Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review.","journal":"Infection and drug resistance"},{"date":"2026 Feb 24","pmid":"41733825","title":"Travel-Related Challenges of Chikungunya Virus and Vaccination Options.","journal":"Journal of epidemiology and global health"},{"date":"2026 Apr","pmid":"41679405","title":"New progress in the global expansion and prevention of chikungunya fever.","journal":"Acta tropica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"IXCHIQ","companyName":"Centre Hospitalier Universitaire de la Réunion","companyId":"centre-hospitalier-universitaire-de-la-r-union","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:46:10.916663+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}